Apport diagnostique de l'HBME-1 et de l'anti-cytokératine-19 en pathologie thyroïdienne: etude rétrospective de 163 cas [Diagnostic contribution of HBME-1 and anti-cytokeratin-19 antibodies in thyroid pathology: a retrospective study of 163 cases]
Details
Serval ID
serval:BIB_20C27EB2D2C4
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Apport diagnostique de l'HBME-1 et de l'anti-cytokératine-19 en pathologie thyroïdienne: etude rétrospective de 163 cas [Diagnostic contribution of HBME-1 and anti-cytokeratin-19 antibodies in thyroid pathology: a retrospective study of 163 cases]
Journal
La Tunisie medicale
ISSN
0041-4131 (Print)
ISSN-L
0041-4131
Publication state
Published
Issued date
05/2005
Peer-reviewed
Oui
Volume
83
Number
5
Pages
274-278
Language
french
Notes
Publication types: Clinical Trial ; English Abstract ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
The objective of our study was to estimate the expression of 2 antibodies HBME-1 and anti-cytokeratin-19 and their diagnostic importance in thyroid pathology.
163 thyroid lesions were retrospectively examined by immnohistochemistry.
92% (46/50 cases) of papillary carcinomas expressed HBME-1 as well as 50% (8/16 cases) of follicular carcinomas and 15% (6/40 cases) of follicular adenomas. 8 insular carcinomas, 5 anaplastic carcinomas, 20 cases of Basedow disease and lymphocytic thyroiditis, and the 24 cases of nodular goiters did not express it or very focally. Anti-cytokératine-19 marked 92% of papillary carcinomas, 56.2% of follicular carcinomas, 100% of the medullar carcinomas and 45% of follicular adenomas. Whereas the cases of anaplastic carcinomas, Basedow disease, thyroiditis and the cases of nodular goiters were negative or focally marked.
HBME-1 is an excellent marker for papillary carcinoma which can be helpful in the diagnosis of its follicular variant; the association with anti-cytokératine-19 increases its specificity.
163 thyroid lesions were retrospectively examined by immnohistochemistry.
92% (46/50 cases) of papillary carcinomas expressed HBME-1 as well as 50% (8/16 cases) of follicular carcinomas and 15% (6/40 cases) of follicular adenomas. 8 insular carcinomas, 5 anaplastic carcinomas, 20 cases of Basedow disease and lymphocytic thyroiditis, and the 24 cases of nodular goiters did not express it or very focally. Anti-cytokératine-19 marked 92% of papillary carcinomas, 56.2% of follicular carcinomas, 100% of the medullar carcinomas and 45% of follicular adenomas. Whereas the cases of anaplastic carcinomas, Basedow disease, thyroiditis and the cases of nodular goiters were negative or focally marked.
HBME-1 is an excellent marker for papillary carcinoma which can be helpful in the diagnosis of its follicular variant; the association with anti-cytokératine-19 increases its specificity.
Keywords
Antibodies, Biomarkers/analysis, Biomarkers, Tumor/analysis, Biomarkers, Tumor/immunology, Diagnosis, Differential, Humans, Immunohistochemistry, Keratins/analysis, Keratins/immunology, Retrospective Studies, Sensitivity and Specificity, Thyroid Diseases/diagnosis, Thyroid Diseases/immunology, Thyroid Neoplasms/diagnosis, Thyroid Neoplasms/immunology
Pubmed
Create date
17/10/2023 9:55
Last modification date
20/10/2023 6:10
Usage data
